Primary Site >> Pancreatic Cancer
Gene >> TGFBR1
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Enhanced expression of the type II transforming growth factor beta receptor in human pancreatic cancer cells without alteration of type III receptor expression. PMID: 8389240 |
Ref: Attenuated ALK5 receptor expression in human pancreatic cancer: correlation with resistance to growth inhibition. PMID: 8760600 |
Ref: Presence of two signaling TGF-beta receptors in human pancreatic cancer correlates with advanced tumor stage. PMID: 9365135 |
Ref: Transfection of the type I TGF-beta receptor restores TGF-beta responsiveness in pancreatic cancer. PMID: 9754660 Ref: Genetic alterations of the transforming growth factor beta receptor genes in pancreatic and biliary adenocarcinomas. PMID: 9850059 |
Ref: Smad6 suppresses TGF-beta-induced growth inhibition in COLO-357 pancreatic cancer cells and is overexpressed in pancreatic cancer. PMID: 10049697 Ref: Progress in cancer genetics: lessons from pancreatic cancer. PMID: 10436774 Ref: The TGF-beta signaling inhibitor Smad7 enhances tumorigenicity in pancreatic cancer. PMID: 10498890 Ref: Overexpression of Smad2 and colocalization with TGF-beta1 in human pancreatic cancer. PMID: 10505717 Ref: Enhanced expression of the type II transforming growth factor-beta receptor is associated with decreased survival in human pancreatic cancer. PMID: 10547197 |
Ref: Molecular genetics of ductal pancreatic neoplasia. PMID: 17031113 |
Ref: Altered expression of TGFB receptors and mitogenic effects of TGFB in pancreatic carcinomas. PMID: 11408925 Ref: Molecular diagnosis of pancreatic cancer. PMID: 11490843 Ref: Soluble type II transforming growth factor-beta (TGF-beta) receptor inhibits TGF-beta signaling in COLO-357 pancreatic cancer cells in vitro and attenuates tumor formation. PMID: 11555612 |
Ref: Attenuation of the TGF-beta-Smad signaling pathway in pancreatic tumor cells confers resistance to TGF-beta-induced growth arrest. PMID: 12802277 |
Ref: Targeting endogenous transforming growth factor beta receptor signaling in SMAD4-deficient human pancreatic carcinoma cells inhibits their invasive phenotype1. PMID: 15289325 |
Ref: Smad7 abrogates transforming growth factor-beta1-mediated growth inhibition in COLO-357 cells through functional inactivation of the retinoblastoma protein. PMID: 15811853 |
Ref: Antitumor activity of ALK1 in pancreatic carcinoma cells. PMID: 17230504 Ref: Dissecting the role of TGF-beta type I receptor/ALK5 in pancreatic ductal adenocarcinoma: Smad activation is crucial for both the tumor suppressive and prometastatic function. PMID: 17297450 Ref: Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. PMID: 17804750 Ref: Antitumor activity of TGF-beta inhibitor is dependent on the microenvironment. PMID: 18229422 |
Ref: Transforming growth factor-beta induces nerve growth factor expression in pancreatic stellate cells by activation of the ALK-5 pathway. PMID: 19639490 Ref: Tgfbr1 haploinsufficiency inhibits the development of murine mutant Kras-induced pancreatic precancer. PMID: 19951995 |
Ref: Molecular markers for novel therapeutic strategies in pancreatic endocrine tumors. PMID: 23211371 |
Ref: Identification of biomarkers for the prognosis of pancreatic ductal adenocarcinoma with miRNA microarray data. PMID: 25791160 |
Ref: Gene expression profile analysis of pancreatic cancer based on microarray data. PMID: 27035876 Ref: Negative control of TRAIL-R1 signaling by transforming growth factor beta1 in pancreatic tumor cells involves Smad-dependent down regulation of TRAIL-R1. PMID: 27492861 Ref: Proteinase-Activated Receptor 2 Is a Novel Regulator of TGF-beta Signaling in Pancreatic Cancer. PMID: 27916875 |
Ref: miR-202 Diminishes TGFbeta Receptors and Attenuates TGFbeta1-Induced EMT in Pancreatic Cancer. PMID: 28373289 Ref: Negative regulation of TGF-beta1-induced MKK6-p38 and MEK-ERK signalling and epithelial-mesenchymal transition by Rac1b. PMID: 29229918 Ref: The Role of PAR2 in TGF-beta1-Induced ERK Activation and Cell Motility. PMID: 29261154 |
Ref: Linc00462 promotes pancreatic cancer invasiveness through the miR-665/TGFBR1-TGFBR2/SMAD2/3 pathway. PMID: 29899418 Ref: Galunisertib plus gemcitabine vs. gemcitabine for first-line treatment of patients with unresectable pancreatic cancer. PMID: 30318515 |